Pharmaxis shares soar 60 per cent
Pharmaxis shares soared 60 per cent after the company moved closer to securing approval to market its cystic fibrosis drug in Europe.
Pharmaxis shares dive after US review Updated: 11:53, Thursday January 31, 2013 Shares in pharmaceutical company Pharmaxis have dived by more than 40 per cent after its cystic fibrosis treatment received a negative review from advisers to regulators in the United States.